AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd

Link copied
Case Copied 80 min read

FEDERAL COURT OF AUSTRALIA

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2021] FCAFC 222

Appeal from:

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2020] FCA 672;

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd (No 2) [2020] FCA 1092;

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd (No 3) [2020] FCA 1352

File number: NSD 1153 of 2020
Judgment of: NICHOLAS, MARKOVIC AND BURLEY JJ
Date of judgment: 7 December 2021
Catchwords: CONSUMER LAW –  appeal from three judgments of this Court – where appellant sought declaration that there is adequate foundation for certain statements in advertisement for analgesic drug – where appellant bound by previous order restraining them from making certain representations – where primary judge made declarations that appellant breached that order – where primary judge dismissed appellant’s application to re-open matter after judgment given – whether primary judge proceeded on the basis of misapprehension of the facts and/or the manner in which an argument was advanced – whether certain representations conveyed by appellant’s advertising, training and point of sale materials – where appellant provided table of unqualified “accepted representations” to primary judge – where trial conducted on the basis that those representations were not treated as unqualified – appeal allowed
Legislation:

Australian Consumer Law (Sch 2 to the Competition and Consumer Act 2010 (Cth))

Federal Court Rules 2011 (Cth)

Cases cited:

AFT Pharmaceuticals (AU) Pty Limited v Reckitt Benckiser (Australia) Pty Limited [2020] FCAFC 45

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2020] FCA 672

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd (No 2) [2020] FCA 1092

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd (No 3) [2020] FCA 1352

Australian Competition and Consumer Commission (ACCC) v Coles Supermarkets Australia Pty Ltd [2014] FCA 634; (2014) 317 ALR 73

Reckitt Benckiser (Australia) Pty Limited v AFT Pharmaceuticals (AU) Pty Limited [2018] FCA 1552

Division: General Division
Registry: New South Wales
National Practice Area: Commercial and Corporations
Sub-area: Regulator and Consumer Protection
Number of paragraphs: 122
Date of hearing: 19 February 2021
Counsel for the Appellant: Mr P Crutchfield QC and Mr L Merrick
Solicitor for the Appellant: Corrs Chambers Westgarth
Counsel for the Respondent: Mr B Walker SC and Mr A Vincent
Solicitor for the Respondent: HWL Ebsworth Lawyers

ORDERS

NSD 1153 of 2020
BETWEEN:

AFT PHARMACEUTICALS (AU) PTY LTD

Appellant

AND:

RECKITT BENCKISER (AUSTRALIA) PTY LTD

Respondent

ORDER MADE BY:

NICHOLAS, MARKOVIC AND BURLEY JJ

DATE OF ORDER:

7 DECEMBER 2021

THE COURT ORDERS THAT:

1.The appeal be allowed.

2.Orders 1 to 10 and 12 to 17 made in proceeding NSD 252 of 2019 on 24 September 2020 be set aside and in lieu thereof the following declarations and orders be made:

(a)declarations that:

(i)there is an adequate scientific foundation for the following statements as presented in, and in the context of, the advertisement attached as Annexure…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Austra... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] FCAFC 222
Decision Date

CaseChat Overview and Summary

AFT Pharmaceuticals (AU) Pty Ltd appealed against three judgments of the Federal Court, challenging the findings of the primary judge that certain statements in their advertisement for an analgesic drug lacked an adequate scientific foundation. The primary judge had made declarations that AFT breached a previous order restraining them from making certain representations, and dismissed AFT’s application to reopen the matter after judgment was given. AFT contended that the primary judge misapprehended the facts or the manner in which an argument was advanced. The court was required to decide whether the primary judge's findings were based on a misapprehension of the facts or the manner in which an argument was advanced, and whether certain representations conveyed by AFT's advertising, training, and point of sale materials had an adequate scientific foundation. The court found that the primary judge had indeed proceeded on the basis of a misapprehension of the facts. The primary judge had considered that AFT accepted during the trial that the impugned statements could be assessed on the basis that they had been made in an unqualified manner and without appropriate reference to the Daniels 2018 study. However, AFT had never made such a concession. The court found that there was an adequate scientific foundation for the statements in question, as presented in, and in the context of, the advertisement, training aid, and point of sale material. The appeal was allowed, and the primary judge's orders were set aside and replaced with new declarations and orders that there was an adequate scientific foundation for the statements in question. The cross-claim was dismissed, and the respondent was ordered to pay the applicant's costs of the proceeding and the appeal.

Orders

Orders of the court

1. The appeal be allowed.

2. Orders 1 to 10 and 12 to 17 made in proceeding NSD 252 of 2019 on 24 September 2020 be set aside and in lieu thereof the following declarations and orders be made:

(a) declarations that:

(i) there is an adequate scientific foundation for the following statements as presented in, and in the context of, the advertisement attached as Annexure A:

A. “maxigesic GET BETTER1 & FASTER1 PAIN RELIEF THAN PARACETAMOL OR IBUPROFEN ALONE1”;

B. “A new clinical study of moderate to severe dental pain shows that Maxigesic ® provides better and faster pain relief than both paracetamol and ibuprofen alone, at maximum dosage1”;

C. “Faster onset of meaningful pain relief than for Paracetamol or Ibuprofen alone1”;

D. “Maxigesic ® is a unique Paracetamol + Ibuprofen combination that provides superior analgesic efficacy for patients than either Paracetamol or Ibuprofen alone1”;

E. “PROVEN TO PROVIDE MORE EFFECTIVE PAIN RELIEF IN A NEW CLINICAL STUDY”; and

F. “36% MORE EFFECTIVE THAN IBUPROFEN1 & 78% MORE EFFECTIVE THAN PARACETAMOL1”,

(together, the Maxigesic Statements),

(ii) there is an adequate scientific foundation for the Maxigesic Statements as presented in, and in the context of, the training aid attached as Annexure B;

(iii) there is an adequate scientific foundation for the following statement as presented in, and in the context of, the point of sale material attached as Annexure C:

A. Maxigesic Based on a new study1 GET BETTER PAIN RELIEF than paracetamol or ibuprofen alone1; and

(b) orders that:

(i) the cross-claim dated 1 March 2019 be dismissed; and

(ii) the respondent pay the applicant’s costs of the proceeding.

3. The respondent pay the appellant’s costs of the appeal.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

At the hearing of the appeal, senior counsel for AFT accepted that if ground 2 of the appeal failed then ground 1 could not succeed.2. The decisions of the primary judge2.1 The judgment 2.1.1The advertisements, the claims and the representations The 2019 marketing materials which were before the primary judge comprised: the new advertisement, which was published in pharmacy and dental trade journals in February and March 2019; a training aid used by AFT’s sales staff in their dealings with pharmacies; and various POS materials displayed in pharmacies. The new advertisement and the training aid were relevantly the same and were directed to health professionals, whereas the POS materials were directed to a wider audience, including consumers: see judgment at [10]. At [12]-[13] the primary judge set out the claims in the new advertisement and the training aid that AFT sought to justify by reference to scientific evidence:12The new advertisement and the training aid contain the following statements, for which AFT contends that it has an adequate scientific basis:(1)“maxigesic GET BETTER1 & FASTER1 PAIN RELIEF THAN PARACETAMOL OR IBUPROFEN ALONE1”;(2)A new clinical study of moderate to severe dental pain shows that Maxigesic® provides better and faster pain relief than both paracetamol and ibuprofen alone, at maximum dosage1;(3)“Faster onset of meaningful pain relief than for Paracetamol or Ibuprofen alone1”(4)“Maxigesic® is a unique Paracetamol+ Ibuprofen combination that provides superior analgesic efficacy for patients than either Paracetamol or Ibuprofen alone1”(5)“PROVEN TO PROVIDE MORE EFFECTIVE PAIN RELIEF IN A NEW CLINICAL STUDY”; and(6)“36% MORE EFFECTIVE THAN IBUPROFEN1 & 78% MORE EFFECTIVE THAN PARACETAMOL1”.Footnote 13AFT pleads that the reference denoted by “1” in both the new advertisement and the training aid reads as follows:(a)(in the middle of the page) “Daniels study results assessed on the intent-to-treat (ITT) population with adjustment for the use of rescue medication. Sensitivity analysis confirms primary endpoint independent of rescue medication adjustment1.” (mid-page footnote); and(b)(at the foot of the page) “References: Daniels SE, Atkinson HC, Stanescu I, and Frampton C (2018), “Analgesic Efficacy of an Acetaminophen/Ibuprofen Fixed­ dose Combination in Moderate to Severe Postoperative Dental Pain: A Randomized, Double-blind, Parallel-group, Placebo-controlled Trial”, Clinical Therapeutics 40 ‍(10): 1765 – 1776. Result achieved in a trial of post-operative pain relief after removal of at least 2 impacted third molars using Maxigesic® fixed-dose combination (Paracetamol 975mg/Ibuprofen 292.5mg) compared with Paracetamol 975mg or Ibuprofen 292.5mg alone 4 times a day (Paracetamol 3900mg or Ibuprofen 1170mg per day). Maxigesic® 975/292.5mg combination is bioequivalent to Maxigesic® 1000/300mg Australian combination at full dose (Aitken et al, J Bioequiv Availab, 10:5). Research sponsored by AFT Pharmaceuticals…” (bottom page footnote)

Ratio Decidendi

Legal Principle Established

Insofar as Reckitt’s cross-claim was concerned, the primary judge concluded, on the basis of her findings, that the five unqualified representations i.e. the accepted representations (see [15] above) did not have an adequate scientific foundation. Her Honour said at [198] that:The reason for these conclusions is that each of the representations is unlimited as to nature of pain, dosage and treatment duration. As explained above, the scientific evidence is addressed to much more specific comparisons and the expert evidence does not support a conclusion that there is an adequate scientific basis for extrapolating from the Daniels 2018 study and the wider body of scientific evidence to the unqualified representations. Even the evidence of Dr Russo and Professor Thisted, that the Daniels 2018 study provides an adequate scientific foundation for the statements in the new advertisement, must be understood in the context of their agreement that the study is not directly informative concerning degree of pain relief in contexts other than the acute pain dental impaction setting. As I understood their evidence on this point, it was predicated upon an assumption that the claims in the advertisement are addressed to the treatment of acute pain.(Emphasis added.) The primary judge found that there was also no adequate scientific foundation for making the restrained representation: see judgment at [199]. 2.2 The re-opening judgment AFT brought an application for leave to re-open pursuant to r 39.04 of the Federal Court Rules 2011 (Cth) on the basis that the primary judge had misapprehended “that AFT accepted during the running of the trial that the impugned statements could be assessed on the basis that they had been made in an unqualified manner and without appropriate reference to the Daniels 2018 study”: see re-opening judgment at [12]. AFT submitted that it had never made the concession that the accepted representations were unqualified. The primary judge considered AFT’s submission in the context of two documents which had been provided to the Court by AFT in the course of the hearing. The first document was provided by AFT during opening submissions and is in the following terms:Representations which the Applicant accepts arise1.Maxigesic is more efficacious than paracetamol or ibuprofen alone.2.Maxigesic provides better and faster pain relief than both paracetamol or ibuprofen alone.3.Maxigesic provides better and faster pain relief than both paracetamol or ibuprofen alone at maximum dosage.4.Maxigesic provides 36% more effective pain relief than ibuprofen and 78% more effective pain relief than paracetamol.5. Maxigesic provides better pain relief than paracetamol and ibuprofen alone.We will refer to this document in these reasons as the Representations Document. The second document was handed up by AFT at the commencement of its closing submissions and is reproduced in the judgment at [39] (see [15] above). This document contains the same representations as in the Representations Document but also notes in which of the 2019 marketing materials AFT says those representations arise.